Wall Street analysts predict that Koninklijke DSM (NASDAQ:RDSMY) will report $0.29 earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Koninklijke DSM’s earnings. Koninklijke DSM reported earnings per share of $0.23 in the same quarter last year, which would suggest a positive year over year growth rate of 26.1%. The firm is scheduled to announce its next quarterly earnings results on Monday, November 6th.
On average, analysts expect that Koninklijke DSM will report full year earnings of $1.18 per share for the current year, with EPS estimates ranging from $1.14 to $1.21. For the next financial year, analysts forecast that the business will report earnings of $1.24 per share, with EPS estimates ranging from $1.19 to $1.28. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Koninklijke DSM.
RDSMY has been the subject of several analyst reports. Zacks Investment Research upgraded Koninklijke DSM from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. HSBC Holdings plc began coverage on Koninklijke DSM in a report on Friday, September 1st. They set a “buy” rating for the company.
Shares of Koninklijke DSM (RDSMY) traded up 0.61% during mid-day trading on Wednesday, hitting $21.51. The company’s stock had a trading volume of 36,078 shares. The company has a 50-day moving average price of $20.47 and a 200-day moving average price of $18.94. Koninklijke DSM has a 1-year low of $14.50 and a 1-year high of $21.60. The stock has a market cap of $15.05 billion and a PE ratio of 17.75.
Koninklijke DSM Company Profile
Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.
Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com